VentriPoint Diagnostics Ltd

VentriPoint Diagnostics raises $61k CAD in shares to pay debenture interest, preserving liquidity while boosting investor confidence and supporting its AI‑cardiac diagnostics growth.

VentriPoint Diagnostics highlights unseen U.S. cardiovascular market shifts, offering investors insight into future growth and strategic opportunities in cardiac tech.

VentriPoint Diagnostics Ltd. transforms heart disease diagnosis with 3‑D imaging tech, delivering precise, cost‑effective heart models for clinicians worldwide.

VentriPoint Diagnostics Ltd. transforms heart‑disease imaging into 3‑D models, but its steep financial volatility threatens this breakthrough tech’s future.

Ventripoint Diagnostics: a low‑cost, bolt‑on 3‑D cardiac imaging solution that boosts accuracy, drives subscription revenue, and scales without new hardware—transforming hospital diagnostics.

VentriPoint Diagnostics transforms ultrasound images into 3‑D heart models, rivaling MRI quality while lowering costs. Learn how its tech and market buzz could reshape cardiac diagnostics.

VentriPoint Diagnostics turns 2‑D images into 3‑D heart models, boosting heart disease diagnosis for cardiologists.

VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics transforms 2‑D imaging into 3‑D heart models, boosting early heart‑disease detection. Learn how their tech and growth strategy shape the future of cardiac care.

VentriPoint Diagnostics Ltd.